Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 29,343

Document Document Title
WO/2014/194209A1
Disclosed herein are compounds having a formula: or a pharmaceutically acceptable salt thereof, as well as therapeutic methods, medicaments, and compositions related thereto.  
WO/2014/188843A1
The purpose of the present invention is to provide a method for producing tetrahydrofuran with high reaction yield using erythritol that is a biomass or 3,4-dihydroxytetrahydrofuran that can be induced readily from erythritol as a raw ma...  
WO/2014/187343A1
Disclosed are a benzofuran derivative, a preparation method therefor, and a medical application thereof, specifically relating to a compound represented by general formula (I), a stereoisomer thereof, a hydrate thereof, a solvate thereof...  
WO/2014/188762A1
The present invention is a radiation-sensitive resin composition which contains a polymer having a structural unit that contains an acid-cleavable group and a compound represented by formula (1). In formula (1), R1 represents a monovalen...  
WO/2014/184682A9
Provided herein is technology relating to imaging agents for positron emission tomography (PET) and particularly, but not exclusively, to a gonadotropin-releasing hormone (GnRH) antagonist radiolabeled with positron emitting nuclides and...  
WO/2014/184682A1
Provided herein is technology relating to imaging agents for positron emission tomography (PET) and particularly, but not exclusively, to a gonadotropin-releasing hormone (GnRH) antagonist radiolabeled with positron emitting nuclides and...  
WO/2014/183211A1
Discloses is a process for preparation of a compound of formula 11, or a derivative thereof, wherein PG1 is an alcohol protecting group. Also, disclosed are intermediates and processes for their preparation. The compound of formula 11 ca...  
WO/2014/186035A1
The present application provides novel inhibitors of indoleamine 2,3-dioxygenase-1 and/or indoleamine 2,3-dioxygenase-2 and/or tryptophan 2,3-dioxygenase, metabolites thereof, and phannaceutically acceptable salts or prodrugs thereof. Al...  
WO/2014/182688A1
The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that modulate the activity of the Mas receptor, and are useful in methods of treatment and alleviation of d...  
WO/2014/180979A9
This invention relates to a new process for the synthesis of 5-hydroxymethylfurfural (HMF) from saccharides. In particular this invention relates to a new process for the dehydration of monosaccharides having 6 carbon atoms (hexoses), di...  
WO/2014/180979A1
This invention relates to a new process for the synthesis of 5-hydroxymethylfurfural (HMF) from saccharides. In particular this invention relates to a new process for the dehydration of monosaccharides having 6 carbon atoms (hexoses), di...  
WO/2014/180271A1
Revealed in the present invention is a method for preparing Afatinib (I): using 2-nitrile-4-[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino- 5-[(S)- (tetrahydrofuran-3-yl)oxy]aniline (II) and 4-fluoro-3-chloroaniline (III) as starting ma...  
WO/2014/182244A1
The present invention provides a polymer comprising an aliphatic backbone having a plurality of aromatic rings bonded thereon, said plurality of aromatic rings comprising a first aromatic ring type that has an alkyl halide group substitu...  
WO/2014/182873A1
The present disclosure provides novel furanone compounds, or pharmaceutically acceptable salts, solvates or prodrugs thereof, as Raf kinase, especially BRAF kinase, inhibitors, which are useful therapeutic agents for treatment of Raf kin...  
WO/2014/181788A1
The present invention provides: a novel α-substituted glycineamide derivative or a pharmacologically acceptable salt thereof; a pharmaceutical composition containing the α-substituted glycineamide derivative or a pharmacologically acce...  
WO/2014/182171A1
Disclosed is a method of making 5-formyl-2-furoic acid and furan- 2,5-dicarboxylic acid. The method involves the use of 5-keto-aldonic acids as intermediates, as these can be subjected to ring formation by a cyclodehydration reaction und...  
WO/2014/182673A1
The present invention relates to compounds of Formula (la) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that modulate the activity of the Mas receptor, and are useful in methods of treatment and alleviation of d...  
WO/2014/179156A1
5-(hydroxymethyl) furan-2-carbaldehyde (HMF)-sulfonates and a method of preparing the same are described. The method involves reacting a mixture of 5-(hydroxymethyl)furfural (HMF), with at least one of a) a trifluoromethanesulfonate anhy...  
WO/2014/177593A1
The present invention relates to Amorfrutin analogues and stereoisomeric forms, solvates, hydrates, conjugates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of ...  
WO/2014/178389A1
Provided is a new compound having glycogen synthase activation potency, high muscular transition, minimal activation of receptor PPAR, and a high degree of safety. Provided is a compound represented by the following general formula, or a...  
WO/2014/178381A1
 Provided is a new compound having glycogen synthase activation potency, but minimal activation of receptor PPAR, and a high degree of safety. A compound represented by general formula [I], or a pharmaceutically acceptable salt there...  
WO/2014/177464A3
The invention relates to inhibitors of the NHR2 tetramerization and their use as tumor therapeutics (e.g. against acute myeloid leukemia (AML)), cytostatics, and diagnostic agents.  
WO/2014/174416A3
A method of dehydration of at least one compound (A) comprising, in the chain form, -at least one hydroxyl group and -at least one carbonyl functionality selected from the group consisting of aldehyde (CHO), ke- tone (CO) and carboxylic ...  
WO/2014/173973A1
The invention provides a process for the preparation of monoethylene glycol from sucrose comprising the steps of: i) hydrolysing sucrose to form a reaction product stream comprising glucose and fructose; ii) separating the reaction produ...  
WO/2014/176151A1
The present application relates to perfume delivery systems and consumer products comprising such perfume delivery systems, as well as processes for making and using such perfume delivery systems and consumer products. Such perfume deliv...  
WO/2014/175713A1
The present invention relates to a pharmaceutical composition comprising a 5-membered heterocyclic compound, having an analgesic effect, and a derivative thereof. More particularly, the present invention relates to a preparation method f...  
WO/2014/170909A3
The present invention provides a novel process for the preparation of pomalidomide crystalline Form I. The present invention also provides a process for the purification of pomalidomide.  
WO/2014/172363A3
The present invention relates novel heterocyclic analogs of combretastatin, their synthesis, and their use as anti-cancer compounds. In particular, compounds of Formula (I), Formula (II), and Formula (V) are provided.  
WO/2014/167108A1
The invention relates to tetrahydrofuran derivatives of general formula (I), wherein X stands for ⋆-(C=O)-O-, ⋆-(CH2)n-O-, or ⋆-(CH2)n-O-(C=O)-, wherein * represents the point of bonding to the tetrahydrofuran ring and n has the va...  
WO/2014/169214A1
This invention provides processes to convert biomass, including wood and agricultural residues, to levulinic acid and co-products. Some variations treat feedstock with steam and/or hot water to produce an extract liquor containing hemice...  
WO/2014/165827A1
Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demye...  
WO/2014/163500A1
2,5-Furandicarboxylic acid and methyl acetate are prepared in a continuous process, comprising -introducing a 5-methoxymethylfurfural-containing feedstock, an oxygen-containing gas, an oxidation catalyst and an acetic acid-containing sol...  
WO/2014/157574A1
Provided are: a new material useful as an organic electroluminescent element material, namely a condensed fluoranthene compound having a heteroatom on an indeno[3,2-b] fluoranthene backbone; a material for an organic electroluminescent e...  
WO/2014/159559A1
The disclosure provides compounds of formula I or II, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infe...  
WO/2014/158838A1
A process is described for converting HMF to FDCA, comprising dissolving a quantity of HMF in water to form an aqueous solution including HMF, combining the aqueous solution including HMF with an oxygen source in the presence of a homoge...  
WO/2014/155291A1
The invention provides processes for the manufacture of a compound of formula (IA ). The invention further provides improved methods for the conversion of the compound of formula (I A ) into pregabalin.  
WO/2014/159802A1
The present invention provides compounds of Formula (I) or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulator...  
WO/2014/159741A1
The present disclosure provides methods for purifying a 5-(halomethyl)furfural composition, including 5-(chloromethyl)furfural, at operating conditions that decrease or minimize the decomposition or degradation of 5-(chloromethyl)furfura...  
WO/2014/159226A1
A method is disclosed for making an unsaturated glycitan ester by reacting intramolecular condensates of glycitols having four or more carbons with a metathesis-derived unsaturated fatty acid in the presence of an alkaline catalyst and u...  
WO/2014/154676A1
Disclosed is a method for the isomerisation of glucose by reduction to sorbitol and subsequent oxidation into fructose, in which the redox cofactors NAD+/NADH and NADP+/NADPH are regenerated in a one-pot reaction, wherein one of the two ...  
WO/2014/157021A1
The compound expressed by formula (1) [in the formula, X represents a hydrogen atom, a fluorine atom, chlorine atom, or bromine atom, and Y represents a hydrogen atom, a fluorine atom, chlorine atom, or bromine atom] that is useful as a ...  
WO/2014/160940A2
Compounds, methods, and compositions are provided for the treatment of cancer, neurological disorders, and fibrotic disorders. Specifically, the invention includes administering an effective amount of a compound of Formula I, II, or III,...  
WO/2014/159738A2
Provided are solid forms of 5-(halomethyl)furfural, including a crystalline form of 5- (chloromethyl)furfural. Provided are also methods for preparing solid forms of 5- (halomethyl)furfural by crystallization using certain solvents.  
WO/2014/157238A1
The present invention addresses the problem of providing a photoelectric conversion material that excels in heat resistance and vapor-deposition stability, a photoelectric conversion element using the photoelectric conversion material, a...  
WO/2014/160649A1
This invention pertains generally to antibacterial organic compounds of Formula I as described herein, and pharmaceutical compositions containing such compounds. In certain aspects, the invention pertains to treating infections caused by...  
WO/2014/159738A3
Provided are solid forms of 5-(halomethyl)furfural, including a crystalline form of 5- (chloromethyl)furfural. Provided are also methods for preparing solid forms of 5- (halomethyl)furfural by crystallization using certain solvents.  
WO/2014/157018A1
A novel organic compound represented by a formula (G1) that forms an exciplex emitting light with high efficiency is provided. By the use of the organic compound and an organic compound with an electron-transport property, an exciplex th...  
WO/2014/148591A1
The present invention provides a method for efficiently producing an optically active 1, 2-diol compound from an olefin. The production method for the optically active 1, 2-diol compound is characterized by including: a step in which an ...  
WO/2014/148053A1
This invention relates to a compound with EP4 antagonistic activity, or a pharmaceutically acceptable salt with EP4 receptor antagonistic activities, which is useful in the treatment of cartilage disease. This invention also relates to a...  
WO/2014/146604A1
Provided is a fused ring compound having GPR40 receptor function regulating action, and preparation method and pharmaceutical compositions thereof, and the use thereof in drugs for the treatment and/or prevention of diseases associated w...  

Matches 301 - 350 out of 29,343